CNS biotech Myrobalan Therapeutics raises $24M Series A to enter the clinic

My­robal­an Ther­a­peu­tics has raised $24 mil­lion to en­ter the clin­ic with one of its four CNS ther­a­peu­tic can­di­dates, with the goal of ei­ther re­pair­ing or restor­ing func­tions in pa­tients with neu­rode­gen­er­a­tive con­di­tions.

Neu­ro­science drug dis­cov­ery and de­vel­op­ment has been heat­ing up, with re­cent high-pro­file ap­provals, large start­up fi­nanc­ings and a pair of multi­bil­lion-dol­lar ac­qui­si­tions.

Med­ford, MA-based My­robal­an was formed in mid-2021 and is based on find­ings out of Har­vard re­searcher Zhi­gang He, and has staff in Chi­na as well as the US. It’s a re­union of sorts for CEO Jing Wang, an 18-year biotech vet­er­an who did her PhD in He’s lab in the ear­ly 2000s. The biotech’s oth­er co-founder is MIT pro­fes­sor Guop­ing Feng.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.